Low Systemic Exposure With Targeted Administration of AER-901 (Inhaled Imatinib): Results of a Phase 1 Clinical Trial

Basic mechanisms in pulmonary hypertension

Chair(s): Christina A. Eichstaedt, Christophe Guignabert

Session type: Oral presentation

Gary Burgess

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Use of multi-omics to uncover novel druggable targets of SOX17 in PAH

Eleni Vasilaki

Replay

Poster

Abstract

Slides

Unpicking the Effects of General Control Non-depressible 2 (GCN2) Deficiency in Pulmonary Veno-Occlusive Disease

Max Schwiening

Replay

Poster

Abstract

Slides

Empagliflozin attenuates hypoxia-induced pulmonary arterial remodeling via inhibiting NOTCH3 signaling pathway

Celina De Almeida

Replay

Poster

Abstract

Slides

Proteomic analysis of biomarkers associated with long-term survival in systemic sclerosis-related group 3 pulmonary hypertension in the HYPID study

Valentine Mismetti

Replay

Poster

Abstract

Slides

An endothelial cell subtype is linked with altered Rho-kinase (ROCK)-associated pathways in PAH

Rui Benfeitas

Replay

Poster

Abstract

Slides

Quantitative evaluation of pulmonary arteriolar structural changes in pulmonary arterial hypertension

Gitte Aerts

Replay

Poster

Abstract

Slides

Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors

Julien Grynblat

Replay

Abstract

Slides

Identification of AURKB as a new actor in vascular remodeling in PAH

Sarah-eve Lemay

Replay

Poster

Abstract

Slides

Low Systemic Exposure With Targeted Administration of AER-901 (Inhaled Imatinib): Results of a Phase 1 Clinical Trial

Gary Burgess

Replay

Poster

Abstract

Slides

Neuroinflammation mediates cognitive dysfunction in pulmonary hypertension

Ping Yuan

Replay

Poster

Abstract

Slides

Discussion and Q&A

The ERS International Congress 2023, Milan

#{title}